We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
In a quickly crowding ankylosing spondylitis market, Cimzia maker UCB is working hard stand out with its beyond-the-pill offerings. Back in January, it partnered on a spondyloarthritis social network, and now, it's taking that partnership one step further